NorLux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, 1526, Luxembourg.
Oncology Research Laboratory, Department of Radiation Sciences, Umeå University, 90187 Umeå, Sweden.
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):109-116. doi: 10.1016/j.bbcan.2017.02.007. Epub 2017 Mar 1.
Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies. Additionally, this multifaceted RTK inhibitor was reported to be a tumor suppressor, a stem cell regulator, and a modulator of different cellular phenotypes. This mini-review provides a concise and up-to-date summary about the known functions of LRIG1 and its related family members, with a special emphasis on underlying molecular mechanisms and the opportunities for harnessing its therapeutic potential against cancer.
富含亮氨酸重复序列和免疫球蛋白样结构域的蛋白 1（LRIG1）是受体酪氨酸激酶（RTKs）的内源性反馈调节剂，最近研究表明其可抑制多种类型的恶性肿瘤的生长。此外，这种多功能 RTK 抑制剂被报道为肿瘤抑制因子、干细胞调节剂以及不同细胞表型的调节剂。这篇迷你综述简要概述了 LRIG1 及其相关家族成员的已知功能，并特别强调了其潜在的分子机制及其在癌症治疗中的应用潜力。
